Stockreport

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

FibroGen, Inc  (FGEN) 
Last fibrogen, inc earnings: 3/2 04:01 pm Check Earnings Report
PDF FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2 m [Read more]